Atrial Fibrillation in Adults

SECTION 1: Clinical Overview

1.1 Summary

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial electrical activation with consequent deterioration of mechanical atrial function. [1] It represents the most common sustained cardiac arrhythmia in clinical practice, affecting an estimated 59.7 million individuals globally as of 2019. [2] The condition is electrocardiographically defined by the replacement of consistent P waves with rapid oscillations or fibrillatory waves varying in amplitude, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact. [1]

The clinical significance of AF extends beyond its arrhythmic manifestations. AF is independently associated with a five-fold increase in stroke risk, with approximately 20-30% of all ischemic strokes attributable to AF-related thromboembolism. [3] The condition confers a 1.5- to 2-fold increased mortality risk, primarily mediated through stroke, heart failure, and sudden cardiac death. [4] Furthermore, AF is associated with significant cognitive decline, dementia, and reduced quality of life independent of stroke occurrence. [5]

Contemporary management follows the ESC "CC to ABC" pathway: Confirm the diagnosis with ECG documentation, Characterize AF using the 4S-AF scheme (Stroke risk, Symptom severity, Severity of AF burden, and Substrate severity), followed by the ABC pathway comprising Anticoagulation/Avoid stroke, Better symptom control with rate and rhythm control strategies, and Comorbidity and cardiovascular risk factor optimization. [1] This integrated approach has demonstrated superior outcomes compared to traditional management strategies. [6]

1.2 Key Facts

• Definition: A supraventricular tachyarrhythmia with chaotic atrial electrical activation, diagnosed by ECG showing absence of discrete P waves, presence of fibrillatory waves, and irregularly irregular R-R intervals for at least 30 seconds. [1]
• Global Prevalence: Approximately 2-4% of the adult population, with projected increases of 60% by 2050 due to population aging. [2]
• Lifetime Risk: 1 in 3 individuals of European ancestry over age 55 will develop AF; lifetime risk is approximately 37% for individuals at index age 55. [7]
• Mortality Impact: AF is associated with a 1.5-fold increased mortality in men and a 2-fold increased mortality in women. [4]
• Stroke Risk: AF increases stroke risk 5-fold; AF-related strokes are more severe with higher mortality and morbidity. [3]
• Age Distribution: Prevalence increases from less than 0.5% at age 40-50 to approximately 10-17% in those aged ≥80 years. [8]
• Sex Differences: Higher age-adjusted incidence in men (1.5:1), but women have higher stroke risk at any CHA2DS2-VASc score level. [9]
• Pathognomonic Finding: Irregularly irregular pulse on palpation; ECG showing fibrillatory baseline without discernible P waves.
• Gold Standard Diagnosis: 12-lead ECG or single-lead rhythm strip demonstrating AF for ≥30 seconds duration. [1]
• First-line Anticoagulation: Direct oral anticoagulants (DOACs) preferred over vitamin K antagonists for non-valvular AF. [10]
• Rate Control Target: Lenient rate control (less than 110 bpm at rest) is non-inferior to strict control (less than 80 bpm) for most patients. [11]
• Primary Stroke Prevention: Approximately 80% relative risk reduction achievable with appropriate anticoagulation. [12]

1.3 Clinical Pearls

Diagnostic Pearl: "The 30-Second Rule" A clinical diagnosis of AF requires a standard 12-lead ECG or single-lead ECG tracing showing AF for at least 30 seconds. [1] This duration threshold distinguishes sustained AF from short runs of atrial ectopy or non-sustained atrial arrhythmia. Device-detected AF episodes less than 5 minutes duration warrant clinical assessment but may not require immediate anticoagulation. [13]

Examination Pearl: "The Pulse Deficit" Always compare the apical heart rate (auscultation) with the radial pulse rate (palpation). In AF with rapid ventricular response, some cardiac contractions are too weak to generate a palpable peripheral pulse, creating a "pulse deficit." A deficit > 10 bpm indicates poor rate control and hemodynamic compromise.

Treatment Pearl: "DOAC Dominance" Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for stroke prevention in AF without moderate-to-severe mitral stenosis or mechanical heart valves. [10] DOACs provide consistent anticoagulation without routine monitoring, have fewer drug and food interactions, and demonstrate superior or non-inferior efficacy with significantly lower intracranial hemorrhage rates. [14]

Pitfall Warning: "The Valvular AF Exception" The term "valvular AF" specifically refers to AF in patients with moderate-to-severe mitral stenosis (typically rheumatic) or mechanical prosthetic heart valves. [1] These patients MUST receive vitamin K antagonists (warfarin) rather than DOACs, as DOACs are contraindicated. Biological prosthetic valves and other valve diseases (including aortic stenosis, mitral regurgitation) do not preclude DOAC use.

Mnemonic: "CHA2DS2-VASc Scoring" Congestive heart failure (1), Hypertension (1), Age ≥75 (2), Diabetes (1), Stroke/TIA/Thromboembolism (2), Vascular disease (1), Age 65-74 (1), Sex category (Female = 1). Anticoagulation is recommended for men with score ≥2 and women with score ≥3. [1]

Emergency Pearl: "Stability Dictates Strategy" In hemodynamically unstable AF (hypotension, pulmonary edema, ongoing ischemia, reduced consciousness), proceed immediately to synchronized DC cardioversion without delay for rate-controlling medications. [15] Hemodynamic instability is an indication for emergency cardioversion regardless of anticoagulation status or AF duration.

Exam Pearl: "Holiday Heart Syndrome" Acute alcohol consumption can trigger AF in otherwise healthy individuals without structural heart disease—termed "Holiday Heart Syndrome." [16] This often occurs after binge drinking episodes and typically resolves spontaneously within 24-48 hours. Counsel patients that alcohol abstinence significantly reduces AF recurrence.

Evidence Pearl: "Early Rhythm Control Advantage" The EAST-AFNET 4 trial demonstrated that early rhythm control within 12 months of AF diagnosis reduces the composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome by 21% compared with usual care. [17] This supports proactive rhythm control in appropriate candidates.

1.4 Why This Matters Clinically

Patient Outcomes: Untreated AF carries profound consequences. The most devastating is cardioembolic stroke, which occurs without warning in 20-30% of cases as the first manifestation. [3] AF-related strokes have higher mortality (approximately 25% at 30 days) and worse functional outcomes compared with non-AF strokes. [18] Early detection and appropriate anticoagulation can prevent approximately 80% of these strokes. [12]

Heart Failure Connection: AF and heart failure form a bidirectional relationship—each condition predisposes to and worsens the other. Tachycardia-induced cardiomyopathy from uncontrolled AF can reduce ejection fraction by 20-30%, which may be reversible with adequate rate or rhythm control. [19] The CASTLE-AF trial demonstrated that catheter ablation in patients with AF and heart failure with reduced ejection fraction improves survival and reduces heart failure hospitalizations. [20]

Healthcare Burden: AF accounts for more hospital admissions than any other arrhythmia, with estimated annual costs exceeding $26 billion in the United States alone. [21] Hospitalizations occur for stroke, heart failure, rate/rhythm control, and anticoagulation complications.

Medico-legal Considerations: Failure to calculate stroke risk, offer anticoagulation, or document informed refusal represents a significant source of litigation following embolic events. Proper risk stratification and shared decision-making documentation are essential for medicolegal protection.

Examination Relevance: AF is ubiquitous in clinical examinations (MRCP, USMLE, PLAB, FRACP) because it requires integrated understanding of electrophysiology, hemodynamics, pharmacology, risk stratification, and evidence-based medicine. Examiners expect candidates to demonstrate a structured approach to management.

---

SECTION 2: Classification of Atrial Fibrillation

2.1 Temporal Classification (ESC 2020/2024)

Important Note: Classification may change based on treatment response and clinical decisions. A patient with "permanent" AF may be reclassified to "long-standing persistent" if rhythm control is subsequently pursued. [1]

2.2 Mechanistic Classification

2.3 Etiological Classification

2.4 The 4S-AF Scheme for AF Characterization

The ESC 2020 guidelines introduced the 4S-AF scheme for comprehensive AF characterization: [1]

---

SECTION 3: Epidemiology

3.1 Incidence and Prevalence

• Global Burden: An estimated 59.7 million individuals were living with AF worldwide in 2019, representing a 33.5% increase from 1990. [2]
• Prevalence by Region: Higher in developed nations (2-4%) compared with developing regions (1-2%), attributed to differences in detection, risk factors, and life expectancy.
• Age-Specific Prevalence: less than 0.5% at ages 40-50; 5-8% at ages 70-79; 10-17% at ages ≥80 years. [8]
• Incidence: Approximately 5-8 per 1,000 person-years in the general population; exceeds 20 per 1,000 person-years in those > 80 years. [22]
• Lifetime Risk: 37% for individuals aged 55 years (Rotterdam Study), with similar risk in men and women despite lower age-adjusted incidence in women. [7]
• Projected Increase: AF prevalence is expected to increase 2.5-fold by 2050 due to population aging and improved survival from cardiovascular diseases. [2]
• Underdetection: An estimated 25-40% of AF cases are undiagnosed, often detected incidentally or after stroke. [1]

3.2 Demographics

3.3 Risk Factors

Non-Modifiable Risk Factors

Modifiable Risk Factors

---

SECTION 4: Pathophysiology

4.1 Mechanisms of Atrial Fibrillation Initiation

4.1.1 Ectopic Triggers (Focal Mechanism)

The seminal work by Haissaguerre et al. (1998) established that the majority of paroxysmal AF episodes are initiated by rapid firing from ectopic foci located within the pulmonary veins. [27]

• Anatomical Basis: Sleeves of atrial myocardium extend 1-3 cm into the pulmonary veins, with distinct electrophysiological properties including shorter action potential duration and higher automaticity.
• Cellular Mechanism: Delayed afterdepolarizations (DADs) due to abnormal calcium handling, particularly through RyR2 calcium leak and NCX exchanger activity.
• Triggering Factors: Autonomic imbalance (sympathetic or parasympathetic surges), atrial stretch, inflammation, and oxidative stress.
• Distribution: 94% of triggers originate from pulmonary veins (predominantly left superior PV), with remaining 6% from non-PV sources (coronary sinus, superior vena cava, left atrial posterior wall, ligament of Marshall). [27]

4.1.2 Re-entry and Multiple Wavelets

• Moe's Multiple Wavelet Hypothesis: AF is maintained by multiple independent wavelets of electrical activity circulating randomly through the atria.
• Requirements for Re-entry: Shortened atrial effective refractory period (AERP), slowed conduction velocity, and increased conduction heterogeneity.
• "AF Begets AF": Rapid atrial activation induces electrical remodeling within minutes to hours that promotes AF perpetuation.

4.2 Atrial Remodeling

4.2.1 Electrical Remodeling

Occurs within hours of AF onset and promotes persistence: [28]

4.2.2 Structural Remodeling

Develops over weeks to months with persistent AF:

• Fibrosis: Interstitial and replacement fibrosis disrupts myocyte coupling, creating conduction barriers and enabling re-entry.
• Mediators: TGF-β1, angiotensin II, aldosterone, inflammatory cytokines (IL-6, TNF-α, CRP).
• Cellular Changes: Myocyte hypertrophy, myolysis, glycogen accumulation, and connexin redistribution.
• Left Atrial Enlargement: Progressive dilation further promotes re-entry substrate.

4.2.3 Autonomic Remodeling

• Ganglionated Plexi Hyperactivity: Epicardial fat pads containing autonomic ganglia become hyperactive.
• Autonomic Imbalance: Both vagal and sympathetic activation can trigger and perpetuate AF.
• Clinical Relevance: Ganglionated plexi ablation may improve AF ablation outcomes.

4.3 Thrombogenesis in Atrial Fibrillation

AF creates a prothrombotic state through Virchow's Triad: [3]

Left Atrial Appendage (LAA) Significance:

• 90% of thrombi in non-valvular AF originate from the LAA. [29]

• LAA morphology (chicken wing, cactus, windsock, cauliflower) affects thromboembolic risk.
• LAA occlusion is an alternative to anticoagulation in selected patients.

4.4 Pathophysiology of Heart Failure in AF

Tachycardia-Induced Cardiomyopathy:

• Persistent rapid ventricular rates (usually > 100-120 bpm) cause progressive LV dysfunction.
• Mechanisms: Calcium handling abnormalities, energetic depletion, myocyte apoptosis, extracellular matrix remodeling.
• Reversibility: EF may normalize with adequate rate/rhythm control, typically within 1-6 months. [19]

Loss of Atrial Contribution:

• Atrial contraction contributes 15-25% of ventricular filling.
• Loss disproportionately affects patients with diastolic dysfunction (HFpEF), hypertrophic cardiomyopathy, and mitral stenosis.

---

SECTION 5: Clinical Presentation

5.1 Symptoms

EHRA Symptom Score:

5.2 Physical Examination Findings

Vital Signs:

• Irregularly irregular pulse with variable rate
• Possible discrepancy between apical and radial rates (pulse deficit)
• Blood pressure may be variable beat-to-beat

5.3 Red Flags

[!CAUTION] RED FLAGS - Require Immediate Action:

Hemodynamic Instability

• Systolic BP less than 90 mmHg or signs of shock
• Acute pulmonary edema (bilateral crackles, hypoxia, orthopnea)
• Altered level of consciousness
• Action: Immediate synchronized DC cardioversion

Cardiac Ischemia

• Ongoing chest pain with ischemic ECG changes
• Elevated troponin in context of rapid AF
• Action: Rate control, anticoagulation, cardiology consultation

Pre-excited AF (WPW)

• Very rapid irregular wide-complex tachycardia (> 200 bpm)
• Variable QRS morphology with delta waves
• Action: AVOID AV nodal blocking agents (digoxin, verapamil, adenosine); DC cardioversion or procainamide

Acute Neurological Deficit

• Focal weakness, speech disturbance, facial droop
• Acute stroke presentation
• Action: Immediate stroke protocol, CT head, thrombolysis/thrombectomy consideration

Extreme Bradycardia/Asystole

• Tachy-brady syndrome with prolonged pauses > 3 seconds
• Symptomatic bradycardia after AF termination
• Action: Consider temporary pacing, avoid rate-slowing agents

---

SECTION 6: Stroke Risk Assessment

6.1 CHA2DS2-VASc Score

The CHA2DS2-VASc score is the recommended tool for stroke risk stratification in AF: [1]

Stroke Risk by Score:

6.2 Anticoagulation Decision

ESC 2020/2024 Recommendations: [1]

Important Considerations:

• Female sex alone (CHA2DS2-VASc = 1) does not mandate anticoagulation.
• Aspirin is NOT recommended for stroke prevention in AF. [1]
• DOACs are preferred over VKAs for eligible patients. [10]

---

SECTION 7: Bleeding Risk Assessment

7.1 HAS-BLED Score

The HAS-BLED score identifies modifiable bleeding risk factors: [30]

Interpretation:

• Score ≥3: High bleeding risk; emphasizes need to address modifiable factors
• HAS-BLED should NOT be used to withhold anticoagulation but to identify and correct modifiable risk factors
• Modifiable factors: Uncontrolled hypertension, labile INR, concomitant antiplatelet/NSAIDs, excess alcohol

7.2 Other Bleeding Risk Scores

---

SECTION 8: Investigations

8.1 Bedside Investigations

8.2 Laboratory Investigations

8.3 Imaging

8.4 Additional Investigations

---

SECTION 9: Management

9.1 Management Algorithm

                        ┌─────────────────────────────────────────────────────────────┐
                        │            ADULT ATRIAL FIBRILLATION PATHWAY                │
                        │                    (ESC 2020/2024)                          │
                        └─────────────────────────────────────────────────────────────┘
                                                    │
                                                    ▼
                              ┌───────────────────────────────────────────┐
                              │        CONFIRM AF DIAGNOSIS (CC)          │
                              │  • 12-lead ECG or rhythm strip ≥30 sec    │
                              │  • Characterize with 4S-AF scheme         │
                              └───────────────────────────────────────────┘
                                                    │
                        ┌───────────────────────────┴───────────────────────────┐
                        │                                                       │
                        ▼                                                       ▼
              ┌─────────────────────┐                           ┌─────────────────────┐
              │  HEMODYNAMICALLY    │                           │      STABLE         │
              │     UNSTABLE?       │                           │                     │
              │  (Hypotension, HF,  │                           │                     │
              │   Ischemia, LOC)    │                           │                     │
              └─────────┬───────────┘                           └──────────┬──────────┘
                        │                                                  │
                        ▼                                                  ▼
              ┌─────────────────────┐               ┌───────────────────────────────────────┐
              │   EMERGENCY DC      │               │           ABC PATHWAY                  │
              │   CARDIOVERSION     │               ├───────────────────────────────────────┤
              │ • Synchronized shock│               │                                       │
              │ • 120-200J biphasic │               │  A: Anticoagulation/Avoid Stroke      │
              │ • Heparin if not    │               │     • CHA2DS2-VASc assessment         │
              │   anticoagulated    │               │     • DOACs first-line                │
              └─────────────────────┘               │     • VKA for valvular AF             │
                                                    │                                       │
                                                    │  B: Better Symptom Control            │
                                                    │     • Rate control (BB, CCB, digoxin) │
                                                    │     • Rhythm control (AAD, ablation)  │
                                                    │                                       │
                                                    │  C: Comorbidity Optimization          │
                                                    │     • Hypertension, diabetes, OSA     │
                                                    │     • Weight loss, exercise, alcohol  │
                                                    └───────────────────────────────────────┘
                                                                    │
                                    ┌───────────────────────────────┴───────────────────────────────┐
                                    ▼                                                               ▼
                      ┌───────────────────────────┐                               ┌───────────────────────────┐
                      │     RATE CONTROL          │                               │    RHYTHM CONTROL         │
                      │  (Primary strategy or     │                               │  (Preferred if:           │
                      │   combined approach)      │                               │   • Symptomatic           │
                      ├───────────────────────────┤                               │   • less than 12 months duration   │
                      │ Target: less than 110 bpm at rest  │                               │   • Tachycardiomyopathy   │
                      │ First-line:               │                               │   • Young, active)        │
                      │  • Beta-blocker           │                               ├───────────────────────────┤
                      │  • Non-DHP CCB            │                               │ Options:                  │
                      │ Add-on:                   │                               │  • DC Cardioversion       │
                      │  • Digoxin (if HFrEF)     │                               │  • Antiarrhythmic drugs   │
                      │ Avoid in WPW:             │                               │  • Catheter ablation      │
                      │  • Digoxin, Verapamil     │                               │    (PVI ± substrate)      │
                      └───────────────────────────┘                               └───────────────────────────┘

9.2 Anticoagulation Strategy

9.2.1 Direct Oral Anticoagulants (DOACs) - First-Line

9.2.2 Vitamin K Antagonists (Warfarin)

Mandatory Indications:

• Moderate-to-severe mitral stenosis (rheumatic)
• Mechanical prosthetic heart valve

Target INR: 2.0-3.0 (2.5-3.5 for mechanical mitral valve)

Time in Therapeutic Range (TTR): Target > 70% for optimal stroke prevention

9.2.3 Landmark DOAC Trials

9.3 Rate Control

9.3.1 Drug Therapy

9.3.2 Rate Control Targets

RACE II Trial Findings: [11]

• Lenient rate control (less than 110 bpm at rest) was non-inferior to strict control (less than 80 bpm)
• Lenient control easier to achieve with fewer medications and adverse effects
• Strict control may be preferred for symptomatic patients despite lenient rate

9.4 Rhythm Control

9.4.1 Cardioversion

DC Cardioversion:

• Energy: 120-200 J biphasic (synchronized)
• Success rate: 90% for AF less than 48 hours; 75-80% for persistent AF
• Pre-treatment with amiodarone or flecainide improves success and maintenance

Anticoagulation for Cardioversion:

9.4.2 Antiarrhythmic Drugs

"Pill-in-the-Pocket" Approach:

• Self-administered flecainide (200-300 mg) or propafenone (450-600 mg) for infrequent paroxysmal AF
• Requires prior supervised trial in hospital
• Must co-administer AV nodal blocker (beta-blocker or diltiazem)
• Exclude structural heart disease

9.5 Catheter Ablation

9.5.1 Indications (Class I-IIa)

9.5.2 Techniques

Pulmonary Vein Isolation (PVI):

• Goal: Electrical isolation of all four pulmonary veins
• Methods: Radiofrequency (point-by-point), cryoballoon, pulsed-field ablation
• Success rates: 70-80% at 12 months for paroxysmal AF; 50-60% for persistent AF (single procedure) [31]

Additional Targets (for persistent AF):

• Posterior wall isolation
• Mitral isthmus line
• Cavotricuspid isthmus line (if typical flutter)
• CFAE (complex fractionated atrial electrograms) - less commonly performed
• Ganglionated plexi ablation

9.5.3 Complications

9.5.4 Landmark Ablation Trials

9.6 Left Atrial Appendage (LAA) Occlusion

Indications:

• Long-term contraindication to anticoagulation
• High bleeding risk despite anticoagulation indication
• Patient preference after shared decision-making

Devices: WATCHMAN, Amulet (percutaneous); LARIAT (epicardial ligation); surgical excision during cardiac surgery

Evidence:

• PROTECT AF and PREVAIL trials demonstrated non-inferiority of WATCHMAN to warfarin for stroke prevention. [32]
• Dual antiplatelet therapy required for 6 months post-implant, then aspirin lifelong (varies by protocol)

9.7 Comorbidity Management (The "C" in ABC)

---

SECTION 10: Complications

10.1 Thromboembolic Complications

10.2 Cardiac Complications

10.3 Quality of Life Impact

• Depression and anxiety increased 2-fold in AF patients
• Cognitive decline independent of stroke
• Exercise intolerance and functional limitation
• Sleep disturbance
• Sexual dysfunction

---

SECTION 11: Prognosis and Outcomes

11.1 Natural History

Without treatment, AF typically progresses from paroxysmal to persistent to permanent over years to decades. The rate of progression is approximately 5-15% per year and is accelerated by:

• Older age
• Heart failure
• Hypertension
• Diabetes
• Left atrial enlargement
• Obesity

11.2 Outcomes with Treatment

11.3 Ablation Outcomes

---

SECTION 12: Special Populations

12.1 AF in Heart Failure

• Bidirectional Relationship: AF and HF frequently coexist and worsen each other
• CASTLE-AF Evidence: Ablation in HFrEF patients with AF reduces mortality and HF hospitalization by 38% [20]
• Digoxin: May be used for rate control in HFrEF; avoid CCBs (verapamil, diltiazem)
• SGLT2 Inhibitors: Benefit in HFrEF regardless of AF status

12.2 AF in the Elderly (> 80 years)

• Highest AF prevalence (10-17%)
• Highest stroke risk but also highest bleeding risk
• DOACs remain indicated and preferred over warfarin
• Frailty assessment should guide treatment intensity
• Consider reduced DOAC doses as per guidelines

12.3 AF in Pregnancy

• Rate control with beta-blockers (metoprolol, labetalol); avoid atenolol (IUGR)
• Cardioversion is safe at all stages of pregnancy
• Anticoagulation: LMWH in first trimester (teratogenicity of warfarin); warfarin may be used in second/third trimester in high-risk patients; DOACs contraindicated

12.4 Post-operative AF (POAF)

• Incidence: 20-40% after cardiac surgery; 5-10% after major non-cardiac surgery
• Risk Factors: Age, LA enlargement, previous AF, pulmonary disease
• Management: Rate control, anticoagulation if persistent > 48 hours
• Duration: Consider 4 weeks anticoagulation minimum; long-term if ongoing AF or high stroke risk

12.5 Pre-excited AF (WPW)

[!DANGER] Life-Threatening Emergency

• Rapid, irregular wide-complex tachycardia (often > 200 bpm)
• AV nodal blockers (digoxin, verapamil, diltiazem, adenosine) are CONTRAINDICATED as they enhance accessory pathway conduction
• Treatment: Synchronized DC cardioversion OR IV procainamide, ibutilide
• Definitive: Accessory pathway ablation

---

SECTION 13: Evidence and Guidelines

13.1 Major Guidelines

13.2 Landmark Trials Summary

---

SECTION 14: Examination Focus

14.1 Common Exam Questions

MRCP/Written Examinations:

1. "A 72-year-old woman with AF, hypertension, and diabetes is on apixaban. She presents with mechanical mitral valve replacement. What change in anticoagulation is required?"

   • Answer: Switch from apixaban to warfarin (INR 2.5-3.5). DOACs are contraindicated with mechanical valves.

2. "Which anticoagulant is appropriate for a patient with AF and CrCl 12 mL/min?"

   • Answer: Warfarin. All DOACs are contraindicated when CrCl less than 15 mL/min (dabigatran less than 30 mL/min).

3. "A patient with AF develops acute broad-complex irregular tachycardia at 220 bpm with delta waves. What drug should be avoided?"

   • Answer: AV nodal blocking agents (digoxin, verapamil, diltiazem, adenosine). This is pre-excited AF (WPW); use DC cardioversion or procainamide.

Clinical/OSCE Stations:

4. "Calculate the CHA2DS2-VASc score for a 76-year-old woman with hypertension, diabetes, and previous TIA."

   • Answer: Age ≥75 (2) + Hypertension (1) + Diabetes (1) + TIA (2) + Female (1) = 7. High risk; anticoagulation mandatory.

5. "What rate control target would you use for an 80-year-old with AF and HFpEF?"

   • Answer: Lenient rate control less than 110 bpm at rest. Beta-blocker or non-DHP CCB first-line.

14.2 Viva Opening Statement

"Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting 2-4% of the adult population with prevalence increasing to 10-17% in those over 80 years. It is characterized electrocardiographically by the absence of P waves, irregular R-R intervals, and fibrillatory baseline activity. The clinical significance lies in its five-fold increase in stroke risk and association with heart failure and increased mortality.

My approach follows the ESC CC-to-ABC pathway: Confirming AF diagnosis, Characterizing it using the 4S-AF scheme, and then implementing the ABC pathway—Anticoagulation for stroke prevention using CHA2DS2-VASc scoring with DOACs as first-line for eligible patients; Better symptom control through rate or rhythm control depending on individual factors; and Cardiovascular risk factor and Comorbidity optimization.

Evidence from landmark trials including EAST-AFNET 4 and CASTLE-AF has shifted practice toward earlier rhythm control in appropriate patients, while the DOAC trials (RE-LY, ARISTOTLE, ROCKET-AF, ENGAGE AF-TIMI 48) have established direct oral anticoagulants as the standard of care for stroke prevention in non-valvular AF."

14.3 Examiner Questions and Model Answers

Q: "What is the pathophysiology of AF?"

A: "AF involves both triggers and substrate. Triggers predominantly arise from ectopic foci in the pulmonary vein sleeves due to abnormal automaticity and delayed afterdepolarizations. The substrate develops through electrical remodeling—shortening of the atrial effective refractory period within hours through L-type calcium channel downregulation—followed by structural remodeling with interstitial fibrosis mediated by TGF-β, angiotensin II, and inflammatory cytokines. This creates a substrate for multiple re-entrant wavelets, explaining the 'AF begets AF' phenomenon where the arrhythmia promotes its own persistence."

Q: "When would you choose rate control over rhythm control?"

A: "Rate control is appropriate when: the patient is minimally symptomatic (EHRA I); they have permanent AF where rhythm control has been abandoned; they are elderly with multiple comorbidities where aggressive intervention carries high risk; or where previous rhythm control attempts have failed. However, EAST-AFNET 4 has shown that early rhythm control within 12 months of diagnosis improves cardiovascular outcomes, so rhythm control should be strongly considered in recent-onset AF, symptomatic patients, those with heart failure where AF may be contributing, and younger patients with fewer comorbidities."

Q: "How do you manage a patient who presents with acute AF and chest pain?"

A: "This is a red flag scenario requiring urgent assessment. I would initially assess for hemodynamic stability—if unstable, proceed to synchronized DC cardioversion immediately. If stable, I would differentiate whether the chest pain is demand ischemia from rapid AF or primary ACS causing secondary AF. Investigation includes 12-lead ECG for ischemic changes, serial troponins, and echocardiography. Management includes rate control with IV beta-blocker (if no contraindications), anticoagulation with heparin acutely, and treating any underlying ischemia. If ACS is confirmed, dual antiplatelet therapy plus anticoagulation creates 'triple therapy,' and I would involve cardiology for consideration of coronary angiography."

---

SECTION 15: Patient Information

15.1 What is Atrial Fibrillation?

Atrial fibrillation (AF) is an irregular heartbeat caused by abnormal electrical signals in the heart's upper chambers (atria). Instead of beating in a coordinated way, the atria quiver or "fibrillate," causing an irregular and often rapid pulse.

15.2 Why Does AF Matter?

When the heart beats irregularly, blood can pool and form clots, particularly in a small pouch called the left atrial appendage. If a clot travels to the brain, it causes a stroke. AF increases stroke risk five-fold, but this risk can be reduced by 70-80% with blood-thinning medication.

15.3 How is AF Treated?

1. Blood Thinners (Anticoagulants): Medications like apixaban, rivaroxaban, or warfarin help prevent blood clots and stroke. These are the most important part of treatment for most people with AF.

2. Heart Rate Control: Medications like beta-blockers slow the heart rate to reduce symptoms and protect the heart.

3. Heart Rhythm Control: Some patients benefit from treatments to restore normal rhythm, including medications or a procedure called ablation that targets the abnormal electrical signals.

4. Lifestyle Changes: Managing blood pressure, losing weight, treating sleep apnea, reducing alcohol, and regular exercise can significantly improve AF and reduce episodes.

15.4 When to Seek Emergency Help

Contact emergency services immediately if you experience:

• Sudden weakness or numbness in the face, arm, or leg
• Sudden difficulty speaking or understanding speech
• Severe dizziness or fainting
• Chest pain with shortness of breath
• Extremely rapid or very slow heart rate with feeling unwell

---

SECTION 16: References

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612 PMID: 32860505

2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-221. doi:10.1177/1747493019897870 PMID: 31955707

3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. doi:10.1161/01.str.22.8.983 PMID: 1866765

4. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. doi:10.1161/01.cir.98.10.946 PMID: 9737513

5. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013;158(5 Pt 1):338-346. doi:10.7326/0003-4819-158-5-201303050-00007 PMID: 23460057

6. Proietti M, Romiti GF, Olshansky B, et al. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med. 2018;131(11):1359-1366.e6. doi:10.1016/j.amjmed.2018.06.012 PMID: 29969592

7. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-953. doi:10.1093/eurheartj/ehi825 PMID: 16527828

8. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-220. doi:10.2147/CLEP.S47385 PMID: 24966695

9. Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ. 2016;532:h7013. doi:10.1136/bmj.h7013 PMID: 26786546

10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0 PMID: 24315724

11. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373. doi:10.1056/NEJMoa1001337 PMID: 20231579

12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007 PMID: 17577005

13. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-129. doi:10.1056/NEJMoa1105575 PMID: 22236222

14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039 PMID: 21870978

15. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S444-S464. doi:10.1161/CIR.0000000000000261 PMID: 26472995

16. Voskoboinik A, Prabhu S, Ling LH, et al. Alcohol and Atrial Fibrillation: A Sobering Review. J Am Coll Cardiol. 2016;68(23):2567-2576. doi:10.1016/j.jacc.2016.08.074 PMID: 27931615

17. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422 PMID: 32865375

18. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115-1119. doi:10.1161/01.STR.0000166053.83476.4a PMID: 15879330

19. Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol. 2015;66(15):1714-1728. doi:10.1016/j.jacc.2015.08.038 PMID: 26449143

20. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. doi:10.1056/NEJMoa1707855 PMID: 29385358

21. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-320. doi:10.1161/CIRCOUTCOMES.110.958165 PMID: 21540439

22. Krijthe S, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-2751. doi:10.1093/eurheartj/eht280 PMID: 23900699

23. Magnani JW, Norby FL, Agarwal SK, et al. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiol. 2016;1(4):433-441. doi:10.1001/jamacardio.2016.1025 PMID: 27438320

24. Dzeshka MS, Shahid F, Shantsila A, Lip GYH. Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes. Am J Hypertens. 2017;30(8):733-755. doi:10.1093/ajh/hpx013 PMID: 28338788

25. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159-2169. doi:10.1016/j.jacc.2015.03.002 PMID: 25499141

26. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20-28. doi:10.1056/NEJMoa1817591 PMID: 31893513

27. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666. doi:10.1056/NEJM199809033391003 PMID: 9725923

28. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335-2345. doi:10.1016/j.jacc.2014.02.555 PMID: 24613319

29. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-759. doi:10.1016/0003-4975(95)00887-X PMID: 8572814

30. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134 PMID: 20299623

31. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-1274. doi:10.1001/jama.2019.0693 PMID: 30874756

32. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. doi:10.1016/j.jacc.2014.04.029 PMID: 24998121

33. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193 PMID: 38033089

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.